Facebook Icon Print Created with Sketch. Twitter Icon Created with Sketch. Created with Sketch. LinkedIn Icon Green Check Icon Created with Sketch. YouTube Icon Right Arrow Icon Mobile Menu Icon Chevron Right Icon Phone Icon Health Study Area: AutoImmune Disease Health Study Area: Blood Cancer Health Study Area: Cardiovascular Disease Health Study Area: Fibrosis Health Study Area: Gastrointestinal Cancer Health Study Area: Genitourinary Health Study Area: Head and Neck Cancer Health Study Area: Lung Cancer Health Study Area: Melanoma For Caregivers For Clinicians Communities FAQs For Parents For Patients Chevron Icon Bookmark Icon Map Icon Share Icon Direction Arrow Icon Direction Arrow Icon Page Icon Location Icon Search Icon External Link Icon Help Icon Error Icon Glossary Email Icon Gender Both Gender Male Gender Female Created with Sketch. Created with Sketch.

Please Log In/Join Now first, and then use this function!

Welcome to the YERVOY® (ipilimumab) Pregnancy Surveillance Study

What is this study about?

What is this study about?

If you were treated with YERVOY® (ipilimumab) while pregnant, or became pregnant within 90 days of your last infusion, you may be eligible to participate in this pregnancy surveillance study.

A surveillance study monitors patients under special circumstances or those with additional health concerns to evaluate the benefits and potential risks after treatment with a prescribed medication. There is no experimental medicine administered during a surveillance study.

Your participation will provide important information that may be used by future patients and healthcare providers when weighing the benefits and risks of taking YERVOY® during pregnancy.

Your treatment or care will not change in any way as a result of your participation in this study.

For Healthcare Providers

If you are a healthcare provider treating a patient who took or is taking YERVOY® and has become pregnant, you are encouraged to enroll the patient in the study.

Find Out More

If you (or someone you know) were treated with YERVOY® while pregnant, or became pregnant within 90 days of your last infusion, you may be eligible to participate.

Call 1-844-5-YERVOY 
(1-844-593-7869)
Or email: YervoyPregnancy@ubc.com

Participation in this study is entirely voluntary, and you may withdraw at any time.

Live outside the US? Email us to find out if you are eligible for this study: YervoyPregnancy@ubc.com

More Information For Patients

What is the BMS YERVOY® Pregnancy Surveillance Study?

Bristol-Myers Squibb Company, the maker of YERVOY® (ipilimumab), is conducting a study to collect information about the outcomes of women treated with YERVOY® while pregnant. This information is needed because during the development of pharmaceutical products, pregnant women are typically excluded from clinical trials and therefore, limited information is available on the use of YERVOY® during pregnancy.

Your treatment or care will not change in any way as a result of your participation in this study.

Who can participate in the Study?

Women who were treated with YERVOY® while pregnant, or who became pregnant within 90 days of their last infusion of YERVOY®, may be eligible to participate in this study.

Why should I participate in this Study?

Your participation will provide important information that may eventually be used by healthcare providers and future patients when weighing the benefits and risks of taking YERVOY® during pregnancy.

How can I enroll?

To learn more about the YERVOY® Pregnancy Surveillance Study and to find out if you qualify for enrollment, contact a study representative at 1-844-5-YERVOY (1-844-593-7869). You may also ask your healthcare provider to enroll you.

If you are eligible and would like to participate, you will be asked to provide written informed consent to acknowledge your understanding of the study and to provide your permission for your personal healthcare information to be collected. After consent is received, a study representative will contact your healthcare provider to confirm your personal health information.

What will my participation involve once I am enrolled?

Your participation in the study may last throughout your pregnancy and up to 5 years after your delivery date. During this time, you may be asked to participate in a series of brief telephone interviews to collect information about your health and that of your child. This information will be collected at each trimester of pregnancy, at the time of expected delivery, expected delivery +3 months, and every 6 months up to the first 5 years of your child’s life. No clinic or office visits are required during your participation.

The information you provide, as well as any information obtained from your healthcare providers, will be held in strict confidence.

Participation in the study is entirely voluntary, and you may withdraw at any time.

More Information For Health Care Providers

What will my patient's participation involve once she is enrolled?

Once enrolled in the surveillance study, your patient may be asked to participate in brief telephone interviews to collect information about her health and that of her child. This information will be collected at each trimester of pregnancy, at the time of expected delivery, expected delivery +3 months, and every 6 months up to the first 5 years of her child’s life.

All health information provided will be held in strict confidence.

How will the data be collected, analyzed and reported?

Because this is an observational study, there will be no required study visits. All data provided by you and/or your patient will be entered into the study database. The study database will be kept on a secure computer system maintained by the study administrator in accordance with their written security policy.

The success of the YERVOY® surveillance study depends on the continued participation of healthcare providers like you. We greatly appreciate your help with identifying and enrolling patients in the study, and in assisting with the collection of follow-up information during your patient’s participation in the study.

Have questions? Call 855-907-3286 or Email Us

Have questions?
Call 855-907-3286 or Email Us